Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Devices & Dosimetry

Effect of low-level laser therapy on bisphosphonate-treated osteoblasts

The LLLT does not affect the OPG expression in the hFOB cell line, but it may increase the RANKL and M-CSF expressions, thereby resulting in positive effects on osteoclastogenesis and bone remodeling.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors studied human fetal osteoblast cells treated with alendronate, a bisphosphonate, and then irradiated with a low-level laser at 808 nm. They report that laser application increased cell survivability at 72 hours and raised RANKL and M-CSF expression, while OPG was not significantly affected. The study was conducted in cell culture only, so the findings do not establish effects in living bone.

Who or what was studied
Human fetal osteoblastic (hFOB 1.19) cell line treated with alendronate
Wavelengths
808 nm
Limits stated in the abstract
The study was a cell culture experiment, so results may not apply to living bone or patients.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Background

This study investigates the effect of alendronate-treated osteoblasts, as well as the effect of low-level laser therapy (LLLT) on the alendronate-treated osteoblasts. Bisphosphonate decreases the osteoblastic activity. Various treatment modalities are used to enhance the bisphosphonate-treated osteoblasts; however, there were no cell culture studies conducted using a low-level laser.

Methods

Human fetal osteoblastic (hFOB 1.19) cells were treated with 50 μM alendronate. Then, they were irradiated with a 1.2 J/cm2 low-level Ga-Al-As laser (λ = 808 ± 3 nm, 80 mW, and 80 mA; spot size, 1 cm2; NDLux, Seoul, Korea). The cell survivability was measured with the MTT assay. The three cytokines of osteoblasts, receptor activator of nuclear factor κB ligand (RANKL), osteoprotegerin (OPG), and macrophage colony-stimulating factor (M-CSF) were analyzed.

Results

In the cells treated with alendronate at concentrations of 50 μM and higher, cell survivability significantly decreased after 48 h (p < 0.05). After the applications of low-level laser on alendronate-treated cells, cell survivability significantly increased at 72 h (p < 0.05). The expressions of OPG, RANKL, and M-CSF have decreased via the alendronate. The RANKL and M-CSF expressions have increased, but the OPG was not significantly affected by the LLLT.

Conclusions

The LLLT does not affect the OPG expression in the hFOB cell line, but it may increase the RANKL and M-CSF expressions, thereby resulting in positive effects on osteoclastogenesis and bone remodeling.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

Light parameters mentioned

Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.

Energy density (fluence)
1.2 J/cm2
Power
80 mW

How to read a single study: what to check before relying on this kind of research.

Terms in this paper: Low-level laser therapy, Laser. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies